Abstract

Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is an emergent infectious disease that has caused millions of deaths throughout the world. COVID-19 infection's main symptoms are fever, cough, fatigue, and neurological manifestations such as headache, myalgias, anosmia, ageusia, impaired consciousness, seizures, and even neuromuscular junctions' disorders. In addition, it is known that this disease causes a series of systemic complications such as adverse respiratory distress syndrome, cardiac injury, acute kidney injury, and liver dysfunction. Due to the neurological symptoms associated with COVID-19, damage in the central nervous system has been suggested as well as the neuroinvasive potential of SARS-CoV-2. It is known that CoV infections are associated with an inflammation process related to the imbalance of the antioxidant system; cellular changes caused by oxidative stress contribute to brain tissue damage. Although anti-COVID-19 vaccines are under development, there is no specific treatment for COVID-19 and its clinical manifestations and complications; only supportive treatments with immunomodulators, anti-vascular endothelial growth factors, modulating drugs, statins, or nutritional supplements have been used. In the present work, we analyzed the potential of antioxidants as adjuvants for the treatment of COVID-19 and specifically their possible role in preventing or decreasing the neurological manifestations and neurological complications present in the disease.

MeSH

Antioxidants, Oxidative Stress, Stress, Physiological, Therapeutics, Neurologic Manifestations, Sars-Cov-2, Covid-19 Vaccines

Cited by

• The Association Between Antioxidants and COVID-19 Outcomes: a Systematic Review on Observational Studies. Biol Trace Elem Res, 2023
• Habitual salt preference worsens blood pressure in hospitalized hypertensive patients with omicron infection under epidemic-related stress. BMC Public Health, 2024
• Association of Vitamin D Supplementation with Glutathione Peroxidase (GPx) Activity, Interleukine-6 (IL-6) Levels, and Anxiety and Depression Scores in Patients with Post-COVID-19 Condition. Int J Mol Sci, 2025
• Marked elevations in lung and plasma ceramide in COVID-19 linked to microvascular injury. JCI Insight, 2023
• Vascular Endothelial Glycocalyx Damage and Potential Targeted Therapy in COVID-19. Cells, 2022
• Cardiovascular signatures of COVID-19 predict mortality and identify barrier stabilizing therapies. EBioMedicine, 2022
• Potential of Nano-Antioxidants and Nanomedicine for Recovery from Neurological Disorders Linked to Long COVID Syndrome. Antioxidants (Basel), 2023
• Post-COVID Condition and Neuroinflammation: Possible Management with Antioxidants. Antioxidants (Basel), 2025
• Antioxidants: Classification, Natural Sources, Activity/Capacity Measurements, and Usefulness for the Synthesis of Nanoparticles. Materials (Basel), 2021